408 related articles for article (PubMed ID: 18061863)
21. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
22. Management of the BRCA mutation carrier or high-risk patient.
Bordeleau LJ; Lipa JE; Neligan PC
Clin Plast Surg; 2007 Jan; 34(1):15-27; abstract v. PubMed ID: 17307068
[TBL] [Abstract][Full Text] [Related]
23. Choices--and uncertainties--for women with BRCA mutations.
Couzin J
Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
[No Abstract] [Full Text] [Related]
24. [Familial history of ovarian carcinoma: policy].
de Hullu JA; Kets CM; Massuger LF; Ligtenberg ML; van Ham MA; Hoogerbrugge N
Ned Tijdschr Geneeskd; 2011; 155():A2392. PubMed ID: 21262027
[TBL] [Abstract][Full Text] [Related]
25. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
27. Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
Matloff ET; Barnett RE; Bober SL
Cancer J; 2009; 15(1):15-8. PubMed ID: 19197168
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
Haber D
N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
[No Abstract] [Full Text] [Related]
29. A survey of preventive measures among BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
Fackenthal JD; Olopade OI
Nat Rev Cancer; 2007 Dec; 7(12):937-48. PubMed ID: 18034184
[TBL] [Abstract][Full Text] [Related]
31. The prevention of hereditary breast cancer.
Rodriquez E; Domchek SM
Semin Oncol; 2007 Oct; 34(5):401-5. PubMed ID: 17920894
[TBL] [Abstract][Full Text] [Related]
32. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
33. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
34. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
35. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
Michelsen TM; Dørum A; Dahl AA
Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
[TBL] [Abstract][Full Text] [Related]
36. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
Capalbo C; Buffone A; Vestri A; Ricevuto E; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
J Clin Oncol; 2007 Jun; 25(18):2632-4; author reply 2634-5. PubMed ID: 17577048
[No Abstract] [Full Text] [Related]
37. [Recommendations for treatment of individuals at risk for hereditary breast and ovarian carcinoma].
Radulović S; Branković-Magić M; Janković R; Ristanović M
Srp Arh Celok Lek; 2003; 131(7-8):345-50. PubMed ID: 14692152
[TBL] [Abstract][Full Text] [Related]
38. Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Jul; 53(27):603-6. PubMed ID: 15254451
[TBL] [Abstract][Full Text] [Related]
39. Ovarian intraepithelial neoplasia and ovarian cancer.
Gershenson DM; Tortolero-Luna G; Malpica A; Baker VV; Whittaker L; Johnson E; Follen Mitchell M
Obstet Gynecol Clin North Am; 1996 Jun; 23(2):475-543. PubMed ID: 8784888
[TBL] [Abstract][Full Text] [Related]
40. BRCA1 and BRCA2 cancer risks.
Antoniou AC; Pharoah PD; Easton DF; Evans DG
J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
